Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer

Table 2

Immunoreactivity of the 14F7 Mab in normal tissue and lung carcinoma samples.

Histopathological classification	14F7 Mab reactivity
	No. (%)	Intensity range	% of Positive cells
Normal tissues	0/4 (0)	−	0
Non-small-cell lung cancer	26/28 (92.9%)
Squamous cell carcinoma	10/10 (100)	+/+++	1–3
Adenocarcinoma	8/9 (88.8)	++/+++	2/3
Large cell carcinoma	6/7 (85.7)	+/+++	2/3
Others	2/2 (100)	++/+++	1/3
Small cell carcinoma	3/3 (100)	+/+++	2/3

Intensity: − negative, + weak, ++ moderate, +++ intense. Positive cells: 0 (negative to less than 5%), 1 (6–25%), 2 (26–50%) and 3 (more than 50%).